Replies to post #15218 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

The point of the exercise is the OTC/CSE market is full of stupid investors. There's no professional coverage of the stock on OTC/CSE. Analysts who cover stocks on NASDAQ/NYSE can shift the narrative away from what simply comes out of the CEO's mouth in terms of value. It's not hard to see the comparisons that Christopher Moreau has made regarding valuations have some merit. Diamedica primarily has their stroke drug primarily propelling the company above $100M valuation.

www.diamedica.com/pipeline

XORTX only has one real angle that still hasn't reached Phase 2 for kidney disease:

www.xortx.com/pipeline

Bellus Health primarily has it's Chronic Cough angle propelling the company back to a Billion dollars a friggin SECOND TIME AROUND!

bellushealth.com/pipeline/blu-5937/

Meanwhile, Algernon still hasn't fully enrolled 20 people for its so-called IPF/Chronic Cough study in AU/NZ. Had they not F'd that one up to the umpth degree the stock may have never needed to go down this road in the first place. That's the overwhelming f*** Up out of all of this!

Bellus Health, Diamedica Therapeutics, XORTX ALL have independent Analysts covering their stocks. They're not paying someone for a fluff n stuff positive write up on some obscure website targeted at pennyland investors.

HC Wainwright & Co. Maintains Buy on BELLUS Health, Raises Price Target to $14

RBC Capital Initiates Coverage On BELLUS Health with Outperform Rating, Announces Price Target of $8

BTIG Initiates Coverage On BELLUS Health with Buy Rating, Announces Price Target of $9

www.benzinga.com/news/21/09/22925579/hc-wainwright-co-maintains-buy-on-bellus-health-raises-price-target-to-14

This is the current list of Analysts covering Diamedica Therapeutics

FIRM - ANALYST
Craig-Hallum Capital Group - Alexander Nowak
Guggenheim Securities, LLC - Etzer Darout, PhD
Lake Street Capital Markets - Thomas Flaten
Maxim Group, LLC - Jason McCarthy
Oppenheimer & Co. Inc. - Francois Brisebois
ROTH Capital Partners - Elemer Piros, PhD

Oppenheimer analyst Francois Brisebois lowered the price target on DiaMedica Therapeutics Inc. (NASDAQ: DMAC) to $17.00 (from $21.00) while maintaining an Outperform rating.

www.streetinsider.com/Analyst+Comments/DiaMedica+Therapeutics+Inc.+%28DMAC%29+PT+Lowered+to+%2417+at+Oppenheimer/19202384.html

Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX)

Our sum-of-the-parts NPV valuation for the company's lead programs and licensing/milestone payments yields a fair value estimate of $13 per share (C$16), well above current prices near $3 (C$4).

Other analysts for XRTX:

Cantor Fitzgerald Maintains Hold 10.5 PT
7/06/12 BMO Capital Maintains Market Perform 12.0 PT
7/06/12 Brean Capital 16.0 PT

www.benzinga.com/stock/xrtx/ratings

Diamedica Therapeutics outstanding shares = 26.44 Million O/S

Bellus Health outstanding shares = 78.34 Million O/S

XORTX Therapeutics outstanding shares = 12.65 million O/S

Algernon Pharmaceuticals outstanding shares = 1,678,809 O/S

^Look at what Algernon's outstanding share count will be post consolidation compared to the other "pure comparisons". It's many many many times less than all the above. Which means the share price should be able to support a share price well above all of them. Simply do the market cap math.

PEOPLE HERE IN PENNYLAND MUST GET THERE MIND AWAY FROM SHARE PRICE AND THINK IN TERMS OF MARKET CAP. IT'S TIME TO GROW UP AND THE F*** OUT OF PENNYLAND. ONCE AND FOR ALL!

Hey 55 - I can't tell now if whining is about being pissed off or about making more excuses for management to not target a share price @ $25 minimum? Bottom line is - "management" needs to professionally determine what they believe the pipeline is worth for a NASDAQ IPO not Private Placement Pennyland Pimps like Kulwant Malhi. If Christopher Moreau has a shred of decency left, he needs to stick with the lowest possible float and not run up the outstanding shares yet again before getting a real world clinical trial powered for statistical significance across the finish line.

Lest We Forget - common shareholders bought the company at $5 million when there was nothing but preclinical studies done for about 7 molecules stuffed inside of Doc Williams briefcase. A time now, where only one (Ifenprodil) has ever been loaded into the pipeline. So we're now to believe the pipeline remains worth nearly the same price now as in 2018 with DMT/Stroke - Ifenprodil/Small Cell Lung Cancer - Ifenprodil/Chronic Cough - all in the pipeline for 2022?

If we fall for that one - we truly are a collective of stupid people here in Pennyland.

Of note: Thus far, there's more buying today than selling at this price level.

ih.advfn.com/stock-market/USOTC/algernon-pharmaceuticals-qb-AGNPF/trades

peace,

M$